CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs) targeting PD-1 and PD-L1 have become a cornerstone of therapy, improving survival and quality of life in various molecular and clinical subgroups of NSCLC patients, regardless of PD-L1 expression levels (28, 29).